 |
PDBsum entry 4zpv
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viral protein/immune system
|
PDB id
|
|
|
|
4zpv
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
213 a.a.
|
|
|
|
|
|
|
|
|
|
|
212 a.a.
|
|
|
|
|
|
|
|
|
|
|
207 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Viral protein/immune system
|
|
|
Title:
|
|
Structure of mers-coronavirus spike receptor-binding domain (england1 strain) in complex with vaccine-elicited murine neutralizing antibody d12 (crystal form 2)
|
|
Structure:
|
|
D12 fab heavy chain. Chain: h, a. D12 fab light chain. Chain: l, b. Spike glycoprotein. Chain: s, r. Fragment: unp residues 381-588. Synonym: s glycoprotein,e2,peplomer protein. Engineered: yes
|
|
Source:
|
|
Mus musculus. Mouse. Organism_taxid: 10090. Human coronavirus emc (isolate united kingdom/h123990006/2012). Hcov-emc. Organism_taxid: 1263720. Strain: isolate united kingdom/h123990006/2012. Gene: s, 3.
|
|
Resolution:
|
|
|
3.20Å
|
R-factor:
|
0.226
|
R-free:
|
0.281
|
|
|
Authors:
|
|
M.G.Joyce,J.R.Mascola,B.S.Graham,P.D.Kwong
|
|
Key ref:
|
|
L.Wang
et al.
(2015).
Evaluation of candidate vaccine approaches for MERS-CoV.
Nat Commun,
6,
7712.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
08-May-15
|
Release date:
|
21-Oct-15
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Nat Commun
6:7712
(2015)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Evaluation of candidate vaccine approaches for MERS-CoV.
|
|
L.Wang,
W.Shi,
M.G.Joyce,
K.Modjarrad,
Y.Zhang,
K.Leung,
C.R.Lees,
T.Zhou,
H.M.Yassine,
M.Kanekiyo,
Z.Y.Yang,
X.Chen,
M.M.Becker,
M.Freeman,
L.Vogel,
J.C.Johnson,
G.Olinger,
J.P.Todd,
U.Bagci,
J.Solomon,
D.J.Mollura,
L.Hensley,
P.Jahrling,
M.R.Denison,
S.S.Rao,
K.Subbarao,
P.D.Kwong,
J.R.Mascola,
W.P.Kong,
B.S.Graham.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a
cause of severe respiratory disease highlights the need for effective approaches
to CoV vaccine development. Efforts focused solely on the receptor-binding
domain (RBD) of the viral Spike (S) glycoprotein may not optimize neutralizing
antibody (NAb) responses. Here we show that immunogens based on full-length S
DNA and S1 subunit protein elicit robust serum-neutralizing activity against
several MERS-CoV strains in mice and non-human primates. Serological analysis
and isolation of murine monoclonal antibodies revealed that immunization elicits
NAbs to RBD and, non-RBD portions of S1 and S2 subunit. Multiple neutralization
mechanisms were demonstrated by solving the atomic structure of a NAb-RBD
complex, through sequencing of neutralization escape viruses and by constructing
MERS-CoV S variants for serological assays. Immunization of rhesus macaques
confers protection against MERS-CoV-induced radiographic pneumonia, as assessed
using computerized tomography, supporting this strategy as a promising approach
for MERS-CoV vaccine development.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
| |
Links
